Illumina CSO Bentley Paints A Vision For The Future Of Precision Medicine

Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.

Source: Shutterstock

"Genomics might have the capacity to predict what people are suffering from"